Subject: Interesting report on Novo Nordisk
In the absence of a Novo board, I'm posting here. (It also contains some insights into Big Pharma development considerations, and second-order effects of biosimilars <plot spoiler: not so good for the end-consumer>)

Anyhow, I thought it was ten minutes well spent

https://www.wired.com/story/no...

(I think Wired allows a few free looks each month without a subscription)

--- sutton